Listen

Add to my selection

ZERBAXA (ceftolozane/ tazobactam)

Medicine - Posted on Jan 09 2023

Active substance (DCI)

ceftolozane
tazobactam

history (3)

12/14/22

ZERBAXA (ceftolozane/tazobactam) - Traitement des infections chez les enfants (de la naissance à moins de 18 ans)

Key points Approval of reimbursement as for adults, in the marketing authorisation indications only as a last resort for the...

CAV :
54321

icône flèche
1/22/20

ZERBAXA (ceftolozane/ tazobactam)

Key points Favourable opinion for reimbursement in the MA indications only as a last resort for the treatment of patients wi...

CAV :
54321

icône flèche
7/6/16

ZERBAXA, (ceftolozane/tazobactam), cephalosporin and β-lactamase inhibitor

No clinical benefit demonstrated in the management of intra-abdominal infections, acute pyelonephritis and complicated urina...

CAV :
54321

icône flèche

Technical information

ATC code

J01DI54

Manufacturer

MSD FRANCE

Presentation

ZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusion (code CIS : 65166404)
10 flacon(s) en verre de 20 ml (CIP : 34009 300 362 3 5)

All our publications

Bacterial infections

Digestive system diseases - miscellaneous

Kidney diseases

Urologic diseases - miscellaneous